Literature DB >> 28685051

Personalized medicine could transform healthcare.

Sunil Mathur1, Joseph Sutton1.   

Abstract

Personalized medicine (PM) is about tailoring a treatment as individualized as the disease. The approach relies on identifying genetic, epigenomic, and clinical information that allows the breakthroughs in our understanding of how a person's unique genomic portfolio makes them vulnerable to certain diseases. PM approach is a complete extension of traditional approach (One-Size-Fits-All) to increasing our ability to predict which medical treatments will be safe and effective for individual patient, and which ones will not be, based on the patient's unique genetic profile. Implementation of PM has the potential to reduce financial and time expenditure, and increase quality of life and life extension of patients. Knowledge of PM facilitates earlier disease detection via enhanced use of existing biomarkers and detection of early genomic and epigenomic events in disease development, particularly carcinogenesis. The PM approach predominantly focuses on preventative medicine and favours taking pro-active actions rather than just reactive. This approach delays or prevents the need to apply more severe treatments which are usually less tolerated and with increased quality of life and financial considerations. Increasing healthcare costs have placed additional pressure on government funded healthcare systems globally, especially regarding end of life care. PM may increase the effectiveness of existing treatments and negate the inherent problems associated with non-PM approaches. PM is a young but rapidly expanding field of healthcare where a physician can select a treatment based on a patient's genetic profile that may not only minimize harmful side effects and guarantee a more successful result, but can be less cost effective compared with a 'trial-and-error' approach to disease treatment. The less efficient non-PM ('trial-and-error') approach, which can lead to drug toxicity, severe side effects, reactive treatment and misdiagnosis continue to contribute to increasing healthcare costs. Increased patient stratification will allow for the enhanced application of PM and pro-active treatment regimens, resulting in reduced costs and quality of life enhancement.

Entities:  

Keywords:  personalized medicine; tailored therapy; target therapy

Year:  2017        PMID: 28685051      PMCID: PMC5492710          DOI: 10.3892/br.2017.922

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  15 in total

Review 1.  The digital code of DNA.

Authors:  Leroy Hood; David Galas
Journal:  Nature       Date:  2003-01-23       Impact factor: 49.962

2.  The path to personalized medicine.

Authors:  Margaret A Hamburg; Francis S Collins
Journal:  N Engl J Med       Date:  2010-06-15       Impact factor: 91.245

3.  Personalized medicine: part 1: evolution and development into theranostics.

Authors:  F Randy Vogenberg; Carol Isaacson Barash; Michael Pursel
Journal:  P T       Date:  2010-10

4.  Personalized medicine: part 2: ethical, legal, and regulatory issues.

Authors:  F Randy Vogenberg; Carol Isaacson Barash; Michael Pursel
Journal:  P T       Date:  2010-11

Review 5.  Cancer immunotherapy: sipuleucel-T and beyond.

Authors:  Aimee E Hammerstrom; Diana H Cauley; Bradley J Atkinson; Padmanee Sharma
Journal:  Pharmacotherapy       Date:  2011-08       Impact factor: 4.705

Review 6.  Pharmacogenetics/genomics and personalized medicine.

Authors:  Wolfgang Sadée; Zunyan Dai
Journal:  Hum Mol Genet       Date:  2005-10-15       Impact factor: 6.150

Review 7.  Cas9 as a versatile tool for engineering biology.

Authors:  Prashant Mali; Kevin M Esvelt; George M Church
Journal:  Nat Methods       Date:  2013-10       Impact factor: 28.547

Review 8.  The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?

Authors:  Muin J Khoury; Marta Gwinn; Paula W Yoon; Nicole Dowling; Cynthia A Moore; Linda Bradley
Journal:  Genet Med       Date:  2007-10       Impact factor: 8.822

9.  Trastuzumab: updated mechanisms of action and resistance in breast cancer.

Authors:  Thuy Vu; Francois X Claret
Journal:  Front Oncol       Date:  2012-06-18       Impact factor: 6.244

10.  Tracking genomic cancer evolution for precision medicine: the lung TRACERx study.

Authors:  Mariam Jamal-Hanjani; Alan Hackshaw; Yenting Ngai; Jacqueline Shaw; Caroline Dive; Sergio Quezada; Gary Middleton; Elza de Bruin; John Le Quesne; Seema Shafi; Mary Falzon; Stuart Horswell; Fiona Blackhall; Iftekhar Khan; Sam Janes; Marianne Nicolson; David Lawrence; Martin Forster; Dean Fennell; Siow-Ming Lee; Jason Lester; Keith Kerr; Salli Muller; Natasha Iles; Sean Smith; Nirupa Murugaesu; Richard Mitter; Max Salm; Aengus Stuart; Nik Matthews; Haydn Adams; Tanya Ahmad; Richard Attanoos; Jonathan Bennett; Nicolai Juul Birkbak; Richard Booton; Ged Brady; Keith Buchan; Arrigo Capitano; Mahendran Chetty; Mark Cobbold; Philip Crosbie; Helen Davies; Alan Denison; Madhav Djearman; Jacki Goldman; Tom Haswell; Leena Joseph; Malgorzata Kornaszewska; Matthew Krebs; Gerald Langman; Mairead MacKenzie; Joy Millar; Bruno Morgan; Babu Naidu; Daisuke Nonaka; Karl Peggs; Catrin Pritchard; Hardy Remmen; Andrew Rowan; Rajesh Shah; Elaine Smith; Yvonne Summers; Magali Taylor; Selvaraju Veeriah; David Waller; Ben Wilcox; Maggie Wilcox; Ian Woolhouse; Nicholas McGranahan; Charles Swanton
Journal:  PLoS Biol       Date:  2014-07-08       Impact factor: 8.029

View more
  35 in total

1.  Using NGS-methylation profiling to understand the molecular pathogenesis of young MI patients who have subsequent cardiac events.

Authors:  Michelle Thunders; Ana Holley; Scott Harding; Peter Stockwell; Peter Larsen
Journal:  Epigenetics       Date:  2019-04-22       Impact factor: 4.528

Review 2.  Norwegian drug information centres strongly promote person-centred and personalised medicine: a brief report on the achievements and strategy.

Authors:  Jan Schjøtt
Journal:  EPMA J       Date:  2019-04-30       Impact factor: 6.543

Review 3.  The importance of personalized medicine in urological cancers.

Authors:  Fatemeh Khatami; Mandana Hassanzad; Shekoufeh Nikfar; Fateme Guitynavard; Samira Karimaee; Saeyed Saeed Tamehri Zadeh; Keykavos Gholami; AhmadReza Rezaeian; Seyed Ariana Feiz-Abadi; Fatemeh Jahanshahi; Seyed Mohammad Kazem Aghamir
Journal:  J Diabetes Metab Disord       Date:  2021-06-29

4.  From saliva to SNP: non-invasive, point-of-care genotyping for precision medicine applications using recombinase polymerase amplification and giant magnetoresistive nanosensors.

Authors:  Ana Sofia de Olazarra; Dana Lee Cortade; Shan X Wang
Journal:  Lab Chip       Date:  2022-05-31       Impact factor: 7.517

Review 5.  Pharmacogenomic phase transition from personalized medicine to patient-centric customized delivery.

Authors:  Arun Radhakrishnan; Gowthamarajan Kuppusamy; Sivasankaran Ponnusankar; Nikhitha K Shanmukhan
Journal:  Pharmacogenomics J       Date:  2019-12-10       Impact factor: 3.550

6.  Kinetic Release Studies of Antibiotic Patches for Local Transdermal Delivery.

Authors:  Esra Altun; Esra Yuca; Nazmi Ekren; Deepak M Kalaskar; Denisa Ficai; Georgiana Dolete; Anton Ficai; Oguzhan Gunduz
Journal:  Pharmaceutics       Date:  2021-04-23       Impact factor: 6.321

Review 7.  Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia.

Authors:  L Renee Ruhaak; Arnoud van der Laarse; Christa M Cobbaert
Journal:  Ann Clin Biochem       Date:  2019-03-19       Impact factor: 2.057

8.  The decision tool unipolar depression (DTUD): a new measure to facilitate the early identification of patients with major depressive disorder in need of highly specialized care.

Authors:  Frédérique C W van Krugten; Maartje Goorden; Anton J L M van Balkom; Patricia van Oppen; Henricus G Ruhé; Digna J F van Schaik; Werner B F Brouwer; Leona Hakkaart-van Roijen
Journal:  BMC Psychiatry       Date:  2019-06-11       Impact factor: 3.630

9.  The AKR1D1*36 (rs1872930) Allelic Variant Is Independently Associated With Clopidogrel Treatment Outcome.

Authors:  Aleksandra Kapedanovska-Nestorovska; Aleksandar J Dimovski; Zoran Sterjev; Nadica Matevska Geskovska; Ljubica Suturkova; Petar Ugurov; Zan Mitrev; Rodney Rosalia
Journal:  Pharmgenomics Pers Med       Date:  2019-10-21

10.  From hype to reality: data science enabling personalized medicine.

Authors:  Holger Fröhlich; Rudi Balling; Niko Beerenwinkel; Oliver Kohlbacher; Santosh Kumar; Thomas Lengauer; Marloes H Maathuis; Yves Moreau; Susan A Murphy; Teresa M Przytycka; Michael Rebhan; Hannes Röst; Andreas Schuppert; Matthias Schwab; Rainer Spang; Daniel Stekhoven; Jimeng Sun; Andreas Weber; Daniel Ziemek; Blaz Zupan
Journal:  BMC Med       Date:  2018-08-27       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.